Group items tagged

Bayer HealthCare completes acquisition of Teva Pharmaceutical Industries' U.S. animal health business

In 2005, Aché acquired Biosintética Farmacêutica. This acquisition is part of Aché?s strategic plan, which was established in 2004, which aims for, amongst other things, sustained growth, leadership of the domestic market, greater capacity for investment in innovation, and strengthening of the product portfolio. The complementary portfolio and cultural similarities of the two companies were the main factors that led to the acquisition of Biosintética. With this integration, Aché now had 250 therapeutic alternatives and the company moved into new segments such as the cardiovascular area and generic medicines, and the expanded its portfolio in the central nervous system, dermatology, respiratory, oncology and generic medicine areas. Why not visit the Genéricos Biosintética website? - www.genericosbiosintetica.com.br

es marchés émergents devraient donc être au coeur de l'activité de fusions-acquisitions, même si Fitch n'anticipe pas d'opération de grande ampleur. AstraZeneca (AZN.LN) est le groupe le plus susceptible de faire des acquisitions dans les pays émergents, car c'est celui qui est le plus sous pression et qu'il dispose de ressources "considérables", conclut Fitch.

If the buzzword for the pharmaceutical industry in 2012 was “patent cliff,” the key theme for 2013 is “partnership.”

maller R&D organizations and budgets, drug companies are putting more emphasis on working relationships with biotech firms or with academia

collaboration

Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars)

In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors.